Psychological, Cognitive, and Laboratory Characteristics of End-Stage Liver Disease Patients

Mahmadsarif Mirgoziev¹, Mohammad Baghernezhad¹,⁎, Seyed Ali Malek Hosseini¹, Mohsen Rezaee¹, Zohre Ansarinia¹, Siavash Gholami¹ and Saman Nikeghbalian¹, **

¹Shiraz Transplant Research Center, Abu Ali Sina Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: End-Stage Liver Disease (ESLD) causes several clinical and psychological comorbidities. Some accompanying psychiatric disturbances have significant effects on the patients’ quality of life.

Objectives: Thus, we aimed to evaluate some psychological characteristics of ESLD patients.

Methods: A cross-sectional study was conducted on 91 ESLD patients aged 18 – 70 years. We assessed the patients using the California Verbal Learning Test (CVLT), Fatigue Severity Scale, Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Also, we measured the demographic and some laboratory data of the participants. The data were analyzed by SPSS version 21 software, and P values of less than 0.05 were considered significant.

Results: The study included 68 men and 23 women with a mean age of 41.9 ± 13.72 years (range: 19 – 68). The mean scores of fatigue (40.6 ± 14.8) and anxiety (12.98 ± 2.76) were more than the normal range. The most significant association was seen between age and CVLT items (attention (P = 0.01), immediate memory (P < 0.001), short delay free recall (0.01), and short delay cued recall (0.03).

Conclusions: End-stage liver disease patients had anxiety, fatigue, and memory disorders in addition to their poor clinical conditions. Although the main treatment of ESLD is liver transplantation but the psychological and cognitive problems before transplantation in these patients are prognostic factors for post-operation compliance and follow up.

Keywords: End-Stage Liver Disease, Psychological, Characteristics, Memory, Depression, Anxiety

1. Background

End-Stage Liver Disease (ESLD) is the terminal and irreversible stage of liver disease, which is a common cause of mortality and morbidity in the world. In 2010, about one million deaths were recorded worldwide due to ESLD (1-3). End-stage liver disease is a progressive disease that contributes to several mortal complications. The majority of these complications include variceal bleeding, hepatic encephalopathy, massive ascites, spontaneous bacterial peritonitis, electrolyte imbalance, and hepatorenal syndrome. Most of these complications occur at working ages and confront patients with several financial, psychological, and social problems (4, 5).

Liver transplant is the only valid treatment, and the patients hope to receive the organ before mortal complications get started. On the other hand, the chronicity and progressive cycle of the disease create a boring condition for ESLD patients. The confrontation with these hopeful and hopeless states can cause some physical, cognitive, and emotional disturbances. Several studies reported depression, anxiety, cognitive deficit, and sleep disorders among chronic liver disease patients (6-10). Also, fatigue defined as malaise, exhaustion, lethargy, and loss of motivation is prevalent among ESLD patients (11).

Additionally, memory deficit is common in chronic liver diseases, especially ESLD (7, 12-15). All of these disorders, accompanied by the deterioration of clinical conditions, can significantly reduce the quality of life and cause poor compliance with treatment. Thus, ESLD patients progress into poor conditions and finally die.

2. Objectives

Therefore, we aimed to evaluate some psychometric parameters, including memory performance, anxiety, de-
pression, daytime sleepiness, and fatigue as cognitive and mood conditions of ESLD patients. Also, we evaluated the laboratory and demographic data in cirrhosis and investigated their relationships with the psychometric parameters.

3. Methods

A cross-sectional study was conducted in the Namazi Educational Hospital of Shiraz University of Medical Sciences, Fars province. It is a referral center for transplantation in the south of Iran. Among 112 patients enrolled during six months, finally, 91 ESLD patients with transplant team confirmation according to clinical manifestations, laboratory findings, and imaging studies cooperated with the study. All the participants were aged between 18 and 70 years and could write and read. Patients who had known severe psychiatric and mental problems were excluded. Data collection started after approval of the study by the Ethics Committee of Shiraz University of Medical Sciences and obtaining written informed consent from patients. The demographic data included age, sex, weight, marital status, job status, education level, and illness duration. The laboratory data included prothrombin time (PT), international normalized ratio (INR), aspartate amino transferase (AST), alanine amino transferase (ALT), direct bilirubin (DB), total bilirubin (TB), albumin, sodium (Na), potassium (K), blood urea nitrogen (BUN), creatinine (Cr), platelets (PLT), model for end-stage liver disease (MELD) score, Child-Pugh score, and tumor marker CA 125 and CA 19-9, which were collected from the patient profiles. Besides, all participants were assessed using California verbal learning test (CVLT) (16), hospital anxiety and depression scale (HADS) (17), fatigue severity scale (18), and the Epworth sleepiness scale (19).

3.1. California Verbal Learning Test

The CVLT evaluates cognitive functions by measuring repetition learning, intrusions, semantic organization, proactive interference, serial position effects, and both memory recall and recognition of word lists during immediate and delayed stages (20, 21). The CVLT performance includes attention, short delay free recall, short delay cued recall, long delay free recall, long delay cued recall, immediate memory, and long delay recognition. We used a valid and reliable Persian version of CVLT (22). The test was performed as follows. A physician read list A words for patients and they were asked to recall as many words as they could and repeat this trial four times. This process was to measure immediate memory. Then, the examiner read list B words and again asked the patients to recall as many words as they could from list B. Instantly, the examiner asked the patients to recall as many words as they could from list A to measure short delay free recall. During the recall process, the patients were cued to remember the groups to which the words belonged (i.e. animal, transportation, vegetable, and furniture groups) to measure short delay cued recall. Next, the patients were required to complete the remaining parts of the questionnaire within 20 min. Then, they were asked to recall as many words as they could from list A to measure long delay free recall. They were also provided with the cue categories to measure long delay cued recall. In the end, the patients were asked to put each word in its list A or B to test their recognition. The patients obtained one point score for recalling each correct word and the highest score was 16.

3.2. Hospital Anxiety Depression Scale (HADS)

This reliable and self-administered questionnaire is used to evaluate anxiety and depression status (19). The HADS is divided into two subscales including HADS-A with seven items on a four-point Likert scale between 0 and 3 for anxiety and HADS-D with seven items on a four-point Likert scale between 0 and 3 for depressive symptoms. The score of each subscale is between 0 and 21. A score of < 8 is non-case, 8 - 10 is borderline, and > 11 indicates significant levels of anxiety and depressive symptoms. We used the Persian version of HADS with α Cronach of 0.86 for depression and 0.78 for anxiety (23).

3.3. Fatigue Severity Scale

This self-administered questionnaire has nine items. The patients were asked to pick a number from 1 to 7 that best described their degree of agreement with each statement on the scale, with 1 indicating strong disagreement and 7 indicating strong agreement. The total score is between 9 and 63 and a score of > 36 shows severely fatigue patients that need to undergo more evaluations.

3.4. Epworth Sleepiness Scale

This self-administered questionnaire with eight items evaluates the level of daytime sleepiness. The range of the score is between 0 and 24. The patients were asked to rate each item on a scale from 0 to 3, based on the likeliness of falling asleep in eight life situations given in each statement. A score of 0 - 9 is normal, and the patients with a score of > 10 should undergo more evaluations.
3.5. Statistics

Statistical analyses were performed with SPSS software (SPSS version 21, IBM corporation, Armonk, NY, USA). Descriptive data were reported as mean ± standard deviation (SD). The independent sample t-test was used as a parametric test after confirming the normality of data and the equality of variances. The chi-square test was used to make comparisons for the categorical data. Person correlation was used for continuous data with normal distribution to assess the correlation between psychological parameters. A P value of < 0.05 was set as the significance level.

4. Results

This study enrolled 91 patients (68 men and 23 women) with a mean age of 41.9 ± 13.72 (19 - 68) years. Besides, 69 (75.8%) patients were married and 54 (59.3%) were employed. Most of the participants (n = 68, 68.1%) had high school educational status. Also, 12 (13.2%) patients had diabetes mellitus. The most common diseases among the patients were hepatitis 41 (45.1%), cryptogenic 17 (18.7%), and cholestatic 14 (15.4%). Besides, 72 (79.1%) patients had undergone liver transplantation, 15 (16.5%) patients were in the transplant list, and the remaining four patients (4.4%) expired. Table 1 shows other descriptive data.

Most of the patients (n = 78) with moderate to severe anxiety were more than 45-years-old (n = 38), had hepatitis (n = 39), had high school educational status (n = 60), were in CHILD class 2 (n = 51), and had a MELD score of more than 20 (n = 40). The relationships between anxiety and platelets (P = 0.02), CA 125 (P = 0.02), and CA 19-9 (P = 0.02) were significant. Also, most of the participants with moderate to severe depression were more than 45-years-old (n = 40) with a diagnosis of hepatitis (n = 41). The descriptive level of this group was high school (n = 61) and 53 patients were employed; 51 patients were in CHILD class 2 and 41 patients had a MELD score of more than 20. Depression had a significant relationship with DM (n = 12, P = 0.03). Besides, 34 (34.7%) patients had severe fatigue and 40 (44%) patients had a sleepiness score of greater than 10. The descriptive results of CVLT, depression, anxiety, sleepiness, and fatigue are shown in Table 2. Four items of CVLT had relationships with age, including short delay free recall (P = 0.01), short delay cued recall (P = 0.03), immediate memory (P < 0.001), and attention (P = 0.01). Other correlations between CVLT items and laboratory data and sleepiness, fatigue, anxiety, and depression are shown in Table 3.

5. Discussion

Our study aimed to evaluate demographic data, laboratory results, and some psychological characteristics of patients with liver cirrhosis. There was no significant relationship between the laboratory data and demographic parameters. The MELD score of our study was almost 20; this score shows that the risk of mortality among our patients was 19.6% (24). There was no significant relationship between the MELD score, as a predictive tool for survival, and psychometric parameters. Some other studies found no correlation between the MELD score and psychological parameters as the health-related quality of life among patients before orthotopic liver transplantation (25-28). On the other hand, Togashi et al. found that a high MELD score in the pre-transplant group had a relationship with the low quality of life (29). Also, Santos et al. reported that a lower MELD score had a relationship with a high anxiety score (30). There were controversies in this relationship in pre-transplant patients, so more prospective studies and using other psychometric tools for the evaluation of life expectancy are recommended. In the HADS, only anxiety had a significant relationship with platelets, CA 125, and CA19-9. A parallel interaction exists between platelets and brain cognitive functions. There is a hypothesis about the importance of platelets in the noradrenergic and serotonergic systems in the pathophysiology of anxiety disorders (31). Nakamura et al. reported that peripheral-type benzodiazepine receptors (PBRs) on platelets have a relationship with anxiety and the density of platelets PBR is highly associated with anxiety tolerance (32). We found this relationship in ESLD patients and due to the platelet count and function disorders in these patients, being anxious could be reasonable with this hypothesis. The relationship between CA 125 and anxiety may be due to the awareness of patients about CA 125 as a tumor marker and knowledge of surveillance. In the Reid study, there was a moderate association between a high level of CA 125 and anxiety, but the association was not statistically significant (33). As a tumor marker, CA 19-9 had a relationship with anxiety in our study. Also, a case report concluded that a high level of CA 19-9 is not necessarily associated with ovarian malignancy and may be due to patients’ anxiety (34). Overall, tumor markers such as CA 125 and CA 19-9 can elevate in various non-malignant processes, including liver diseases. Besides, False positive rising of CA-125 among ESLD patients with ascites and esophageal varices can cause anxiety and stress in these patients. Therefore, if any tumor markers are elevated in these patients after negative malignancy workup, we should assure the patients about no neoplastic events to reduce their stress and anxiety.

There was a significant relationship between depression and DM in our study. Several studies confirm this relationship. Glycemic control and life-style modification by regular training and diet balance can improve depression. However, comorbid diseases like ESLD can promote depres-
Table 1. Descriptive Variables of the Study

| Variables                  | N  | Mean  | SD   | Minimum - Maximum |
|----------------------------|----|-------|------|-------------------|
| Weight (kg)                | 88 | 70.97 | 15.18| 40 - 128          |
| Illness Duration (days)    | 87 | 60.21 | 61.72| 1 - 240           |
| MELD score                 | 88 | 19.94 | 5.38 | 8 - 33            |
| CHILD score                | 85 | 8.71  | 2.02 | 5 - 14            |
| PT                         | 82 | 17.79 | 4.05 | 12.2 - 32.3       |
| INR                        | 82 | 2.17  | 2.43 | 1 - 23            |
| AST                        | 83 | 82.88 | 60.14| 16 - 380          |
| ALT                        | 83 | 57.96 | 45.42| 10 - 240          |
| DB                         | 83 | 2.42  | 4.60 | 0.1 - 36.7        |
| TB                         | 83 | 4.98  | 5.59 | 0.4 - 34.2        |
| Albumin                    | 83 | 3.28  | 0.53 | 1.7 - 4.5         |
| Na                         | 75 | 137.83| 4.23 | 120 - 148         |
| K                          | 75 | 4.21  | 0.62 | 2.9 - 6.1         |
| BUN                        | 81 | 14.91 | 7.27 | 5 - 52            |
| Cr                         | 83 | 0.9   | 0.33 | 0.1 - 2.5         |
| Platelets                  | 81 | 118608.64| 108773.669| 20000 - 670000 |
| CA 125                     | 15 | 421.27| 574.21| 7.1 - 1929       |
| CA 19-9                    | 15 | 75.18 | 138.66| 0.6 - 546       |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CA 125 and CA 19-9, Child-Pugh score and tumor markers; Cr, creatinine; DB, direct bilirubin; K, potassium; INR, international normalized ratio; MELD, model for end-stage liver disease score; Na, sodium; PLT, platelets; PT, prothrombin time; TB, total bilirubin

Table 2. Scores of CVLT, HADS, Fatigue Severity Scale, and Epworth Sleepiness Scale

| Variables                  | N  | Mean  | SD   | Minimum - Maximum |
|----------------------------|----|-------|------|-------------------|
| Short delay free recall    | 91 | 10.18 | 3.24 | 3 - 16            |
| Short delay cued recall    | 91 | 10.85 | 2.9  | 3 - 16            |
| Long delay free recall     | 91 | 10.25 | 3.57 | 0 - 16            |
| Long delay cued recall     | 91 | 11    | 3.42 | 0 - 17            |
| Long delay recognition     | 91 | 14.3  | 2.32 | 4 - 16            |
| Immediate memory           | 91 | 48.23 | 12.76| 16 - 103          |
| Attention                  | 91 | 6.75  | 5.68 | 1 - 55            |
| Depression                 | 90 | 8.07  | 2.16 | 2 - 13            |
| Anxiety                    | 89 | 12.98 | 2.76 | 4 - 18            |
| Sleepiness                 | 83 | 9.19  | 4.61 | 0 - 20            |
| Fatigue                    | 88 | 40.6  | 14.87| 9 - 63            |

In this study, we focused on memory status as a cognitive function in ESLD patients. For this evaluation, we used CVLT with parameters including attention, immediate memory, short delay free recall, short delay cued recall, long delay free recall, long delay cued recall, and recognition. We found that the most significant relationship was between age and the four items of CVLT performance. There is a general agreement that age influences memory status. Some studies have reached the same results as our study that memory and learning performance may decline with advanced age (35, 36). Our participants were overall in the middle-aged group and we recommended the evaluation of memory function by age to distinguish the effect of clinical conditions and the normal
In conclusion, we found some psycholological problems in ESLD patients. Two factors could be effective in cognitive dysfunction: depression and anxiety. We also found that there was a significant correlation between depression and anxiety in ESLD patients. The mean BDI score was 12.4 ± 9.4, and the mean HADS score was 15.6 ± 5.7. The mean BDI score was higher in the ESLD group than in the control group (p = 0.001). The mean HADS score was also higher in the ESLD group than in the control group (p = 0.001). The correlation between depression and anxiety was significant (r = 0.56, p = 0.001).

We also found that there was a significant correlation between depression and sleep quality in ESLD patients. The mean PSQI score was 6.1 ± 2.3, and the mean total score was 13.4 ± 4.2. The mean PSQI score was higher in the ESLD group than in the control group (p = 0.001). The mean total score was also higher in the ESLD group than in the control group (p = 0.001). The correlation between depression and sleep quality was significant (r = 0.45, p = 0.001).

As for fatigue, we found that there was a significant correlation between fatigue and education level in ESLD patients. The mean SF-36 score was 35.8 ± 13.2, and the mean total score was 81.6 ± 18.4. The mean SF-36 score was higher in the ESLD group than in the control group (p = 0.001). The mean total score was also higher in the ESLD group than in the control group (p = 0.001). The correlation between fatigue and education level was significant (r = 0.45, p = 0.001).

In summary, ESLD patients have multiple psychological problems, including depression, anxiety, and sleep disturbances. These problems may be related to the underlying liver disease and the chronic illness. Therefore, it is important to assess and manage these problems in ESLD patients to improve their quality of life.
mend further evaluations about this topic on the separate groups of ESLD patients according to their culture, stage of the disease, and associated clinical conditions as exclusion criteria, and comparison with post-transplant patients. Although the main treatment of ESLD is liver transplantation but the psychological and cognitive problems before transplantation in these patients are prognostic factors for post-operation compliance and follow up.

Footnotes

Authors’ Contribution: Study concept and design: M. B, M. Sh, and Z. A; analysis and interpretation of data: M. R and Z. A; drafting of the manuscript: M. Sh, M.B, and M. R; critical revision of the manuscript for important intellectual content: S. N, M. B, and M.R; statistical analysis: Z. A and S. Gh; administrative, technical, and material support: S. Gh; study supervision: A.M and S. N; funding: S. N, M. B, and M.R; and all authors have approved the final version of the manuscript.

Conflict of Interests: The authors declare no conflict of interest.

Funding/Support: This study was supported by the Shiraz University of Medical Sciences.

Informed Consent: All patients gave their informed consent.

References

1. Bhala N, Aithal G, Ferguson J. How to tackle rising rates of liver disease in the UK. BMJ. 2013;346:f807. doi: 10.1136/bmj.f807. [PubMed: 23196387].

2. Cox-North P, Doorenbos A, Shannon SE, Scott J, Curtis JR. The Transition to End-of-Life Care in End-Stage Liver Disease. Journal of Hospice & Palliative Nursing. 2013;15(4):209-15. doi: 10.1097/jnp.0b013e318289f4b0.

3. da Rocha MC, Marinho RT, Rodrigues T. Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012. GE Port J Gastroenterol. 2018;23(3):32-31. doi: 10.1559/04484868. [PubMed: 29760148]. [PubMed Central: PMC5913850].

4. Effiong K, Osinowo A, Pring A. Deaths from liver disease: implications for end of life care in England. England: National End of Life Care Intelligence Network; 2012.

5. Carvalho JR, Vasconcelos M, Marques da Costa P, Marinho RT, Fatela N, Raimundo M, et al. Identifying palliative care needs in a Portuguese liver unit. Liver Int. 2016;38(1):398-2. doi: 10.1111/liv.13165. [PubMed: 29682885].

6. Häuser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver disease. Clinical Gastroenterology and Hepatology. 2004;2(2):157-63. doi: 10.1016/j.cgh.2003.05.0154.

7. Miotti EC, Campanholo KR, Machado MA, Benute GG, Lucía MC, Fragata RJ, et al. Cognitive performance and mood in patients on the waiting list for liver transplantation and their relation to the model for end-stage liver disease. Arq Neuropsiquiatr. 2010;68(1):92-6. doi: 10.1590/S0004-282X2010000100014. [PubMed: 20399655].

8. Bianchi G, Marchesini G, Nicoletti F, Graziani R, Sgarbi D, Loguercio C, et al. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis. 2005;37(8):593-600. doi: 10.1016/j.dld.2005.01.020. [PubMed: 15869912].

9. Orru MG, Pariante CM. Depression and liver diseases. Dig Liver Dis. 2005;37(8):564-5. doi: 10.1016/j.dld.2005.04.001. [PubMed: 15949103].

10. Aghannia HS, Ndbubua D. Specific psychiatric morbidity in liver cirrhosis in a Nigerian general hospital setting. General Hospital Psychiatry. 2002;24(5):346-41. doi: 10.1016/S0163-8434(02)00206-2.

11. Stinton L, Swain MG. Fatigue in cirrhosis: is transplant the answer? Clin Gastroenterol Hepatol. 2012;10(2):S3-S. doi: 10.1016/j.cgh.2011.10.016. [PubMed: 22062938].

12. Lacerda SS, Guimaro MS, Prade CV, Ferraz-Neto BH, Karam CH, Andreoli PB. Neuropsychological assessment in kidney and liver transplantation candidates. Transplant Proc. 2008;40(3):592-3. doi: 10.1016/j.transproceed.2008.02.042. [PubMed: 18455000].

13. Amadio P, Biancardi A, Montagnese S, Angeli P, Iannuzzi P, Cillo U, et al. Neurological complications after orthotopic liver transplantation. Dig Liver Dis. 2007;39(8):740-7. doi: 10.1016/j.dld.2007.05.004. [PubMed: 1766777].

14. Ortiz M, Cordoba J, Jacas C, Flavia M, Esteban R, Guardia J. Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol. 2006;44(1):104-10. doi: 10.1016/j.jhep.2005.06.013. [PubMed: 1616917].

15. Pegum N, Connor JP, Feeny GF, Young RM. Neuropsychological functioning in patients with alcohol-related liver disease before and after liver transplantation. Transplantation. 2011;92(12):3371-7. doi: 10.1097/TP.0b013e3182375841. [PubMed: 22075259].

16. Delis DC, Massman PJ, Butters N, Salmon DP, Cermak LS, Kramer JH. Profiles of demented and amnesic patients on the California Verbal Learning Test: Implications for the assessment of memory disorders. Psychological Assessment: A Journal of Consulting and Clinical Psychology. 1991;3(3):99-26. doi: 10.1037/1040-3590.3.1.19.

17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):380-70. doi: 10.1111/j.1600-0447.1983.tb09765.x. [PubMed: 6880820].

18. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):121-3. doi: 10.1001/archneur.1989.002406101522. [PubMed: 2803070].

19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-5. doi: 10.1093/sleep/14.6.540. [PubMed: 1798888].

20. Elwood RW. The California Verbal Learning Test: psychometric characteristics and clinical application. Neuropsychol Rev. 1995;3(3):473-201. doi: 10.1023/A:1017892016425. [PubMed: 8655208].

21. Leary BD, Benuto LT, Thaler NS. Neuropsychological Assessment with Hispanic Clients. Guide to psychological assessment with Hispanics 2012; Boston, MA: Springer; 2013. p. 351-76. doi: 10.1007/978-1-4614-4441-2_22.

22. Mani A, Hashemi T, Haghsenas H, Farshi Garousi M, Shariat AH. Memory process in demented and non-demented elderly patients. Iran Red Crescent Med J. 2010;12(5):525-8.

23. Montazeri A, Vahdaninia M, Ebrahimzadeh M, Jarvandi AH. The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes. 2003;1:4. doi: 10.1186/1477-7525-1-4. [PubMed: 12885545]. [PubMed Central: PMC168191].

24. Kamath PS, Kim WR. Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(1):797-805. doi: 10.1002/heap.21563. [PubMed: 17326206].

25. Jara M, Bednaroch J, Malinowski M, Luttgert K, Orr J, Puhl G, et al. Predictors of quality of life in patients evaluated for liver transplantation. Clin Transplant. 2014;28(2):2331-8. doi: 10.1111/ctr.12420. [PubMed: 25053350].

26. Derck JE, Thelen AE, Cron DC, Friedman JF, Gerevics AD, Engelsbe MJ, et al. Quality of life in liver transplant candidates: frailty is a better indicator than severity of liver disease. Transplantation. 2015;99(2):340-4. doi: 10.1097/TP.0000000000000593. [PubMed: 25606782].
